Clinical trials: Thalidomide, completed
Multiple Myeloma and Plasma Cell Neoplasm
Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma
RATIONALE: Zoledronate may prevent bone loss and stop the growth of cancer cells in bone. Thalidomide may stop the growth of cancer cells by blocking blood flow to the cancer.
- Trial name
- NCT00432458
- Testing
- Thalidomide, zoledronic acid
- Where
- 4 sites in United States
- Volunteers
- 68 people
- Sponsor
- Mayo Clinic
Amyloidosis
Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis
Patients with primary systemic amyloidosis will be treated with CC-5013 (lenalidomide; Revlimid) as a single agent for 3 months.
- Trial name
- NCT00166413
- Testing
- CC-5013
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Mayo Clinic
Recurrent Uterine Corpus Sarcoma, Uterine Corpus Leiomyosarcoma
Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Phase II trial to study the effectiveness of thalidomide in treating patients who have recurrent or persistent cancer of the uterus. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.
- Trial name
- NCT00025220
- Testing
- Thalidomide, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Dexamethasone or Dexamethasone in Combination With Thalidomide as Salvage Therapy
The purpose of this investigational trial is to find out how well patients respond and how long their response lasts when treated with a standard regimen of dexamethasone with or without thalidomide and also find out what kind of…
- Trial name
- NCT00083902
- Testing
- Thalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 190 people
- Sponsor
- University of Arkansas
Multiple Myeloma
Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment
The two objectives of this study are: To increase the 2-year event-free survival from 55%, established with Total Therapy II (UARK 98-026), to 75% in myeloma patients with cytogenetic abnormalities, and from 80%, established with…
- Trial name
- NCT00670631
- Testing
- tandem autologous transplantation
- Volunteers
- 46 people
- Sponsor
- Guido Tricot
Multiple Myeloma
Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Thalidomide may stop the growth of cancer cells by blocking blood flow to the cancer.
- Trial name
- NCT00287872
- Testing
- bortezomib, thalidomide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Multiple Myeloma
Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM
This is a prospective, multicenter phase II trial designed to determine efficacy and safety of a combination chemotherapy consisting of Bendamustine + Dexamethasone + Thalidomide in patients with multiple myeloma (MM) after…
- Trial name
- NCT01526694
- Testing
- Bendamustine, Thalidomide, Dexamethasone
- Where
- 19 sites in Italy
- Volunteers
- 30 people
- Sponsor
- Azienda Ospedaliera di Bolzano
Multiple Myeloma and Plasma Cell Neoplasm
Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.
- Trial name
- NCT00033332
- Testing
- dexamethasone, pamidronate disodium, thalidomide
- Where
- 78 sites in United States, Puerto Rico and 1 more
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma, Effects of Chemotherapy
Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation
This study compared two main different induction protocols used to treat myeloma eligible patients in Brazil. VCD against CTD.
- Trial name
- GBRAM003r (NCT03402295)
- Testing
- Bortezomib, cyclophosphamide, thalidomide, dexamethasone
- Volunteers
- 311 people
- Sponsor
- Grupo de Estudos Multicentricos em Onco-Hematologia
Pain, Chronic, Pain
Understanding and Managing Pain for Thalidomide Survivors
Aim: To explore the pain experience of Thalidomide survivors and propose an effective pain management service, tailored to meet the unique needs of this population.
- Trial name
- TRIUMPH-TS (NCT06398132)
- Testing
- Usual Care
- Where
- United Kingdom
- Volunteers
- 73 people
- Sponsor
- University of Nottingham
Multiple Myeloma
Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy
This is an international multi-center prospective, double randomized, open, controlled phase III study with a phase II entrance phase to compare the therapeutic efficacy of thalidomide plus dexamethasone to conventional melphalan…
- Trial name
- NCT00205751
- Testing
- Thalidomide/Dexamethasone vs Melphalan/Prednisone
- Where
- Austria
- Volunteers
- 350 people
- Sponsor
- Austrian Forum Against Cancer
Multiple Myeloma
Higher Frequency Zoledronic Acid in the Treatment of Multiple Myeloma
The purpose of this study is to determine whether lower than conventional doses of dexamethasone and thalidomide; and a higher dosing frequency of zoledronic acid are effective in the treatment of newly-diagnosed multiple myeloma.
- Trial name
- dtZ (NCT00263484)
- Testing
- dexamethasone, thalidomide, zoledronic acid
- Where
- 10 sites in India, Singapore and 1 more
- Volunteers
- 56 people
- Sponsor
- Gleneagles Hospital
Multiple Myeloma
Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma Patients
This study will evaluate the safety and the efficacy of the association of Melphalan/ Prednisone/Thalidomide/Defibrotide (MPTD) as salvage treatment in advanced and refractory myeloma patients.
- Trial name
- MPTD (NCT00406978)
- Testing
- Prednisone, Melphalan, Thalidomide
- Where
- 5 sites in Italy
- Volunteers
- 24 people
- Sponsor
- Silvio Aime
Endometrial Cancer, Sarcoma
Thalidomide in Treating Patients With Gynecologic Sarcomas
RATIONALE: Thalidomide may stop the growth of gynecologic sarcomas by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who have recurrent or persistent…
- Trial name
- NCT00006005
- Testing
- thalidomide
- Where
- 10 sites in United States
- Sponsor
- New York University Cancer Institute
Extramedullary Plasmacytoma, Isolated Plasmacytoma of Bone
Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
This phase II trial investigates whether patients greater than or equal to 65 years of age diagnosed with myeloma or another plasma cell malignancy will have better outcomes with transplant followed by maintenance therapy, as…
- Conditions
- Extramedullary Plasmacytoma, Isolated Plasmacytoma of Bone, Light Chain Deposition Disease, Primary Systemic Amyloidosis
- Trial name
- NCT01849783
- Testing
- dexamethasone, cisplatin, doxorubicin
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Margarida Magalhaes-Silverman
Multiple Myeloma
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
The study is designed as a Phase III, multi-center trial of tandem autologous transplants versus the strategy of autologous followed by Human Leukocyte Antigen (HLA)-matched sibling non-myeloablative allogeneic transplant.
- Trial name
- NCT00075829
- Testing
- One Autologous Transplant, Non-Myeloablative Allogeneic Transplant, Second Autologous Transplant
- Where
- 36 sites in United States
- Volunteers
- 710 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Multiple Myeloma and Plasma Cell Neoplasm
Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
RATIONALE: Thalidomide may stop the growth of multiple myeloma by stopping blood flow to the tumor. Prednisone may be effective in preventing relapse of multiple myeloma.
- Trial name
- NCT00006890
- Testing
- prednisone, thalidomide
- Where
- 64 sites in United States, Canada
- Volunteers
- 67 people
- Sponsor
- NCIC Clinical Trials Group
Multiple Myeloma
THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM)
The marked activity of thalidomide (thal) and dexamethasone (dex) in relapsed and refractory multiple myeloma (MM) provided the basis for this phase 2 clinical study aimed at investigating the efficacy and toxicity of thal-dex…
- Trial name
- NCT01341262
- Testing
- Thalidomide, Dexamethasone, Zoledronic acid
- Volunteers
- 378 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Recurrent Melanoma, Stage IV Melanoma
Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
This phase II trial is studying how well giving temozolomide together with thalidomide works in treating patients with brain metastases secondary to melanoma.
- Conditions
- Recurrent Melanoma, Stage IV Melanoma, Tumors Metastatic to Brain
- Trial name
- NCT00072163
- Testing
- temozolomide, thalidomide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Intraocular Melanoma, Melanoma (Skin)
Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of melanoma by stopping blood flow to the tumor.
- Trial name
- NCT00005815
- Testing
- temozolomide, thalidomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center